Followers | 831 |
Posts | 120081 |
Boards Moderated | 16 |
Alias Born | 09/05/2002 |
Sunday, September 06, 2015 3:57:25 PM
If we extrapolate the $1.15M daily rate estimated above over a full quarter, we get $104M, which seems like a reasonable number in relation to Teva’s branded Copaxone sales of $870M during 2Q15.
In 2Q15, MNTA would have received $28.1M in Glatopa revenue from NVS if not for the $9M adjustment to reimburse NVS for pre-launch commercialization expenses. Thus, the operating margin on Glatopa appears to be roughly 80%, and MNTA’s cut is half of that, or 40%.
The $104M estimate for 3Q15 Glatopa sales (above) should therefore equate to approximately $41.5M in 3Q15 Glatopa revenue for MNTA.
p.s. One could estimate 3Q15 Glatopa sales by examining script data and making an assumption regarding average selling price. I haven’t done this, but I’m confident that such an approach would yield a result in the same ballpark as the method used in this post.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM